Study of a Series of Patients Treated for Retrograde Cricopharyngeal Muscle Dysfunction Syndrome

University Hospital, Strasbourg, France30 enrolled

Overview

R-CPD syndrome (Retrograde Cricopharyngeal Dysfunction syndrome) is an inability to burp. It is a syndrome whose diagnosis is clinical, and for which there is effective treatment. Recently treated in the United States (first publication in 2019), this syndrome affects many patients in France and is currently unknown. This study concerns a series of patients treated at the University Hospitals of Strasbourg for a syndrome of retrograde dysfunction of the cricopharyngeus muscle having been treated by injection of botulinum toxin into the cricopharyngeus muscle.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Deglutition Disorders

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major subject (≥18 years old) * Subject treated by injection of botulinum toxin into the cricopharyngeal muscle after having had a diagnosis of R-CPD in consultation between January 1, 2022 and December 31, 2022 * Subject not opposing the reuse of their data for the purposes of this research. Exclusion Criteria: * Subject having expressed opposition to participating in the study, * Subject under judicial protection * Subject under guardianship or curatorship

Locations (1)

Service d'ORL et de Chirurgie Cervico-faciale - CHU de Strasbourg - France

Outcomes

Primary Outcomes

Retrospective description of the characteristics of a series of patients treated for dysphagia syndrome

Retrospective study of medical files of patients treated in HUS between January 1, 2022 and December 31, 2022

Time frame: Through study completion, an average of 2 months